prothymosin alpha is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
| Property | Value | Notes |
|---|---|---|
| Amino acid length | 28 residues | Single chain with an acetylated N-terminus |
| Molecular mass | Approximately 3,108 Da | Small shifts occur with counter-ion and water content |
| Isoelectric point | Around 3.5 | Low value follows from the many acidic residues |
| Parent molecule | N-terminal region of prothymosin alpha | Free circulating form in humans is not firmly established |
| Common synonyms | Thymalfasin; T alpha 1 | Older literature also uses the full spelled-out form |
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Krypton-85, with a half-life 10.76 years, is formed by the fission process with a fission yield of about 0.3%. Only 20% of the fission products of mass 85 become 85Kr itself; the rest passes through a short-lived nuclear isomer and then to stable 85Rb. If irradiated reactor fuel is reprocessed, this radioactive krypton may be released into the air. This krypton release can be detected and used as a means of detecting clandestine nuclear reprocessing. Strictly speaking, the stage which is detected is the dissolution of used nuclear fuel in nitric acid, as it is at this stage that the krypton and other fission gases like the more abundant xenon are released. Despite the industrial applications of krypton-85 and the relatively high prices of both krypton and xenon, they are not currently extracted from spent fuel to any appreciable extent even though krypton and xenon both become solid at the temperature of liquid nitrogen and could thus be captured in a cold trap if the flue gas of a voloxidation process were cooled by liquid nitrogen. Increase of fission gases above a certain limit can lead to fuel pin swelling and even puncture, so that fission gas measurement after discharging the fuel from the reactor is most important to make burn-up calculations, to study the nature of fuel inside the reactor, behaviour with pin materials, for effective utilization of fuel and also reactor safety. In addition to that, they are a nuisance in a nuclear reactor due to being neutron poisons, albeit not to the same extent as isotopes of xenon, another noble gas produced by fission.
1 by the Secretary of State for Home Affairs 2 by the London County Council 1 by the Corporation of the City of London 2 (jointly) by the councils of the metropolitan boroughs of the County of London 1 (jointly) by the county councils of Buckinghamshire, Essex, Hertfordshire, Middlesex 1 (jointly) by the county councils of Kent and Surrey 1 (jointly) by the corporations of the county boroughs of Croydon, East Ham, West Ham 1 representative of the Metropolitan Police, appointed by the Secretary of State for Home Affairs 1 representative of the City of London Police appointed by the City Corporation 1 appointed by the Minister of Transport The members of the committee were to appoint a chairman themselves.
Internationally, the company often pairs with other parties to operate locations, or it will outright sell the operational and administrative rights to a franchisee which is given the designation of master franchise for the territory. The master franchise will then be expected to sub-license new stores, provide training support, and ensure operational standards are maintained. In exchange for the oversight responsibilities, the master franchise will receive administrative and advertising support from Burger King Corporation to ensure a common marketing scheme. The 3G Capital ownership group announced in April 2011 that it would begin divesting itself of many corporate owned locations with the intent to increase the number of privately held restaurants to 95%. In 2016, the percentage of privately owned Burger King establishments grew to 99.5%. RBI maintains that approximately 100% of Burger King franchises are privately held restaurants.
=== Mortars === Two-inch mortar – Fielded until the 1980s ML 3-inch mortar – in service through to the 1960s L16 81mm mortar – Main Cold War mortar. ML 4.2-inch mortar – saw service in 1960s L10A1 51mm mortar – Introduced in the 1980s
== Sensitivity to antibiotics == While L. fermentum has been found to have antibiotic resistant properties, other studies have demonstrated that strains of the species are sensitive to some common antibiotics such as gentamicin, cefazolin, penicillin, trimethoprim/sulfamethoxazole, ampicillin, carbenicillin, erythromycin, amikacin, and choloramphenicol.
Sources: en.wikipedia.org
239Pu, a fissile isotope that is the second most used nuclear fuel in nuclear reactors after uranium-235, and the most used fuel in the fission portion of nuclear weapons, is produced from uranium-238 by neutron capture followed by two beta decays. 240Pu, 241Pu, and 242Pu are produced by further neutron capture. The odd-mass isotopes 239Pu and 241Pu have about a 3/4 chance of undergoing fission on capture of a thermal neutron and about a 1/4 chance of retaining the neutron and becoming the next heavier isotope. The even-mass isotopes are fertile but not fissile and also have a lower probability (cross section) of neutron capture; therefore, they tend to accumulate in nuclear fuel used in a thermal reactor, the design of nearly all nuclear power plants today. In plutonium that has been used a second time in thermal reactors in MOX fuel, 240Pu may even be the most common isotope. All plutonium isotopes and other actinides, however, are fissionable with fast neutrons. 240Pu does have a moderate thermal neutron absorption cross section, so that 241Pu production in a thermal reactor becomes a significant fraction as large as 239Pu production. 241Pu has a half-life of 14 years, and has slightly higher thermal neutron cross sections than 239Pu for both fission and absorption. While nuclear fuel is being used in a reactor, a 241Pu nucleus is much more likely to fission or to capture a neutron than to decay. 241Pu accounts for a significant portion of fissions in thermal reactor fuel that has been used for some time.
=== The "creation" of life === One ethical question is whether or not it is acceptable to create new life forms, sometimes known as "playing God". Currently, the creation of new life forms not present in nature is at small-scale, the potential benefits and dangers remain unknown, and careful consideration and oversight are ensured for most studies. Many advocates express the great potential value—to agriculture, medicine, and academic knowledge, among other fields—of creating artificial life forms. Creation of new entities could expand scientific knowledge well beyond what is currently known from studying natural phenomena. Yet there is concern that artificial life forms may reduce nature's "purity" (i.e., nature could be somehow corrupted by human intervention and manipulation) and potentially influence the adoption of more engineering-like principles instead of biodiversity- and nature-focused ideals. Some are also concerned that if an artificial life form were to be released into nature, it could hamper biodiversity by beating out natural species for resources (similar to how algal blooms kill marine species). Another concern involves the ethical treatment of newly created entities if they happen to sense pain, sentience, and self-perception. There is an ongoing debate as to whether such life forms should be granted moral or legal rights, though no consensus exists as to how these rights would be administered or enforced.
Diski was a regular contributor to the London Review of Books; the collections Don't and Why Didn't You Do What You Were Told? collect articles and essays written for the publication. Her memoirs include In Gratitude, The Sixties, Skating to Antarctica, and Stranger on a Train: Daydreaming and Smoking around America With Interruptions, for which she won the 2003 Thomas Cook Travel Book Award. Benjamin Disraeli (1804–1881) novelist, poet, playwright, writer, and prime minister A prolific novelist, the 1840s Disraeli wrote a trilogy of novels with political themes. Coningsby attacks the evils of the Whig Reform Bill of 1832 and castigates the leaderless conservatives for not responding. Sybil; or, The Two Nations (1845) reveals Peel's betrayal over the Corn Laws. These themes are expanded in Tancred (1847). With Coningsby; or, The New Generation (1844). Isaac D'Israeli, (11 May 1766 – 19 January 1848) was a British writer, scholar and the father of British prime minister Benjamin Disraeli. He is best known for his essays and his associations with other men of letters. Michael Pinto-Duschinsky (born June 1943) Hungarian-born author, journalist, scholar, political consultant and writer. Anton Ehrenzweig (27 November 1908 – 5 December 1966) Austrian Jewish British author and theorist on modern art, psychoanalysis and Avant-garde music who wroteThe Psychoanalysis of Artistic Vision and Hearing (1953) and The Hidden Order of Art (1967).
Pilonidal cysts can be itchy and often very painful, and typically occur between the ages of 15 and 35. Although usually found near the coccyx, the condition can also affect the navel, armpit, the cheek, or the genital region, though these locations are much rarer. Signs and symptoms may include:
Sources: en.wikipedia.org
It is usually described as an immunomodulatory peptide rather than a classic circulating hormone. No endocrine gland is known to release it as a primary secretory product, and its measured presence in blood is not firmly established.
Prothymosin alpha is a much larger acidic protein, roughly 111 to 113 residues long, and the thymosin alpha-1 sequence matches its N-terminal region. The small peptide is therefore best understood as a fragment of that parent protein rather than a separate gene product.
Trials and clinical reports have examined chronic hepatitis B and C, use as a vaccine adjuvant, and supportive treatment in some immunodeficiency and oncology settings. Results vary by indication, and regulatory approval differs between countries.
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.